1.Relationship between dengue viral load and clinical characteristics
FEI Yunxi ; ZHANG Xiangbo ; GAO Ling ; GAO Yidan ; LI Ge ; ZHU Xuping ; SHAO Junbin ; WANG WANG ; PAN Jingcao ; CHEN CHEN
Journal of Preventive Medicine 2020;32(4):334-338
Objective:
To determine the relationship between dengue virus load and clinical characteristics, so as to provide basis for dengue fever prevention and treatment.
Methods :
The dengue viral load and typing of 120 patients in Gongshu District of Hangzhou from June to November 2017 were detected by real-time fluorescent quantitative RT-PCR;the clinical indicators of these dengue patients were collected and their correlation with the viral load was analyzed.
Results:
The DNA detection of dengue virus in 120 patients showed that they were all typeⅡ. The median dengue virus load was 3.91×104 copies/mL. All the patients had fever, the average peak temperature was(38.96 ± 0.69)℃. There were 102(85.00%)cases with asthenia;116(96.67%)cases with white blood cell count(WBC)less than 4× 109/L;119(99.17%)cases with platelet count(PLT)less than 100×109/L;114(95.00%)cases with glutamic oxaloacetate transaminase(GOT)more than 40 U/L;81(67.50%)cases with glutamic pyruvate transaminase(GPT)more than 52 U/L;58(48.33%)cases with creatine kinase(CK)more than 210 U/L. There was no significant correlation of dengue virus load with length of hospitalization, peak temperature,duration of fever, WBC,PLT, GOT, GPT and CK(P>0.05). There were 75(62.50%)severe patients, and their median viral load was 9.29×104copies/mL, which was higher than 5.33×103copies/mL in non-severe patients(P<0.05).
Conclusion
The dengue virus load is not related with length of hospitalization,peak temperature,WBC,PLT,GOT,GPT and CK,but with the severity of the disease.
2.Bladder microenvironment actuated proteomotors with ammonia amplification for enhanced cancer treatment.
Hao TIAN ; Juanfeng OU ; Yong WANG ; Jia SUN ; Junbin GAO ; Yicheng YE ; Ruotian ZHANG ; Bin CHEN ; Fei WANG ; Weichang HUANG ; Huaan LI ; Lu LIU ; Chuxiao SHAO ; Zhili XU ; Fei PENG ; Yingfeng TU
Acta Pharmaceutica Sinica B 2023;13(9):3862-3875
Enzyme-driven micro/nanomotors consuming in situ chemical fuels have attracted lots of attention for biomedical applications. However, motor systems composed by organism-derived organics that maximize the therapeutic efficacy of enzymatic products remain challenging. Herein, swimming proteomotors based on biocompatible urease and human serum albumin are constructed for enhanced antitumor therapy via active motion and ammonia amplification. By decomposing urea into carbon dioxide and ammonia, the designed proteomotors are endowed with self-propulsive capability, which leads to improved internalization and enhanced penetration in vitro. As a glutamine synthetase inhibitor, the loaded l-methionine sulfoximine further prevents the conversion of toxic ammonia into non-toxic glutamine in both tumor and stromal cells, resulting in local ammonia amplification. After intravesical instillation, the proteomotors achieve longer bladder retention and thus significantly inhibit the growth of orthotopic bladder tumor in vivo without adverse effects. We envision that the as-developed swimming proteomotors with amplification of the product toxicity may be a potential platform for active cancer treatment.